A GWAS of NHL is being conducted in order to understand the role that genetic variation plays in NHL risk and to identify new genes or genomic regions that may be important in NHL pathogenesis. National and international collaborations have been developed to facilitate accrual of blood or buccal cell DNA on a large set of NHL cases. Through the collaborative efforts of the InterLymph Consortium and the NCI Cohort Consortium that includes studies in the United States, Canada, Europe and Australia, we estimate that approximately 9,000 germline (blood or buccal cell) DNA samples of NHL cases and 3,000 comparable controls will be genotyped at the NCI's Cancer Genomics Research (CGR) Laboratory and subsequently available for GWAS analyses. A team of biostatisticians has been assembled to also create a common control set that will be derived from existing studies to increase sample size of controls. Follow-up will include genotyping and sequence analyses of genomic regions associated with NHL.
Note: Genotype data from this study will be made available in dbGaP once the initial publication is in press at a peer-reviewed journal.